3 Value Stocks with Open Questions

Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are usually cheap for a reason, and a low valuation can reflect underlying business challenges rather than a genuine bargain.

Identifying genuine bargains from value traps is something many investors struggle with, which is why we started StockStory – to help you find the best companies. That said, here are three value stocks facing an uphill battle and some other investments you should look into instead.

EverQuote (EVER)

Forward EV/EBITDA Ratio: 6x

Aiming to simplify a once complicated process, EverQuote (NASDAQ:EVER) is an online insurance marketplace where consumers can compare and purchase various types of insurance from different providers

Why Do We Think Twice About EVER?

1. Excessive marketing spend signals little organic demand and traction for its platform

At $24.81 per share, EverQuote trades at 6x forward EV/EBITDA. Read our free research report to see why you should think twice about including EVER in your portfolio.

Best Buy (BBY)

Forward P/E Ratio: 12.6x

With humble beginnings as a stereo equipment seller, Best Buy (NYSE:BBY) now sells a broad selection of consumer electronics, appliances, and home office products.

Why Are We Bearish on BBY?

1. Ongoing store closures and lackluster same-store sales indicate sluggish demand and a focus on consolidation
2. Weak same-store sales trends over the past two years suggest there may be few opportunities in its core markets to open new locations
3. Widely-available products (and therefore stiff competition) result in an inferior gross margin of 22.6% that must be offset through higher volumes

Best Buy is trading at $83.67 per share, or 12.6x forward P/E. To fully understand why you should be careful with BBY, check out our full research report (it’s free).

Solventum (SOLV)

Forward P/E Ratio: 13.6x

Founded in 1985, Solventum (NYSE:SOLV) develops, manufactures, and commercializes a portfolio of healthcare products and services addressing critical customer and therapeutic patient needs.

Why Does SOLV Fall Short?

1. Core business is underperforming as its organic revenue has disappointed over the past two years, suggesting it might need acquisitions to stimulate growth
2. Estimated sales for the next 12 months are flat and imply a softer demand environment
3. 18.2 percentage point decline in its free cash flow margin over the last five years reflects the company’s increased investments to defend its market position

Solventum’s stock price of $89.05 implies a valuation ratio of 13.6x forward P/E. Check out our free in-depth research report to learn more about why SOLV doesn’t pass our bar.

Stocks We Like More

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.